Pfizer tracks Real-World safety of RSV shot for moms and newborns
NCT ID NCT06482099
Summary
This study is monitoring the safety of the Abrysvo RSV vaccine in pregnant women and their infants after the vaccine's approval in Japan. It involves about 500 pregnant women who receive the vaccine as part of their routine care. Researchers are tracking any side effects in the mothers for 28 days after vaccination and in their babies for 28 days after birth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.